CorMedix (CRMD) Other Non-Current Assets (2010 - 2025)
CorMedix (CRMD) posted Other Non-Current Assets of $642066.0 for Q2 2025, little changed sequentially from $642066.0 in Q1 2025, and up 514.85% YoY from $104426.0 in Q2 2024.
CorMedix (CRMD) Other Non-Current Assets (2010 - 2025) Analysis & Trends
CorMedix has reported Other Non-Current Assets for 15 years, with the latest figure at $642066.0 in Q2 2025.
- Quarterly Other Non-Current Assets rose 514.85% year-over-year to $642066.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $642066.0 (up 514.85% YoY) and the FY2024 annual result came in at $105368.0, up 36.84% from the prior year.
- Other Non-Current Assets held at $642066.0 in Q2 2025 per CRMD's latest filing, from $642066.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $642066.0 in Q1 2025 and troughed at $77000.0 in Q4 2023.
- A 5-year average of $170214.0 and a median of $105226.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets tumbled 73.24% in 2021, then surged 518.33% in 2025.
- Over 5 years, Other Non-Current Assets stood at $102305.0 in 2021, then gained by 0.01% to $102320.0 in 2022, then fell by 24.75% to $77000.0 in 2023, then soared by 36.84% to $105368.0 in 2024, then surged by 509.36% to $642066.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $642066.0, $642066.0, and $105368.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 642,066.00 |
| Mar 31, 2025 | 642,066.00 |
| Dec 31, 2024 | 105,368.00 |
| Sep 30, 2024 | 105,084.00 |
| Jun 30, 2024 | 104,426.00 |
| Mar 31, 2024 | 103,838.00 |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | 102,664.00 |
| Jun 30, 2023 | 102,370.00 |
| Mar 31, 2023 | 102,345.00 |
| Dec 31, 2022 | 102,320.00 |
| Sep 30, 2022 | 114,000.00 |
| Jun 30, 2022 | 121,000.00 |
| Mar 31, 2022 | 129,000.00 |
| Dec 31, 2021 | 102,305.00 |
| Sep 30, 2021 | 134,000.00 |
| Jun 30, 2021 | 138,000.00 |
| Mar 31, 2021 | 136,000.00 |
| Dec 31, 2020 | 191,000.00 |
| Sep 30, 2020 | 500,822.00 |